Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4648 Comments
1656 Likes
1
Haddison
New Visitor
2 hours ago
I understood nothing but I’m reacting.
👍 277
Reply
2
Ramiri
New Visitor
5 hours ago
Indices are experiencing minor retracements, providing potential buying opportunities.
👍 185
Reply
3
Cameil
Regular Reader
1 day ago
Market is testing resistance levels; a breakout could signal further gains.
👍 152
Reply
4
Nasiem
Loyal User
1 day ago
This feels like a clue.
👍 133
Reply
5
Anayely
Consistent User
2 days ago
If only I had read this earlier. 😔
👍 36
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.